ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ASTC / earnings
BNGO (29) EYPT (26) PRPO (30) RPID (34) ⌘ Pro Terminal →

Astrotech Corporation (ASTC) Next Earnings Date & Expected ±12.5% Move

$4.71 -2.69% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.68

Astrotech Corporation (ASTC) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $10.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ASTC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ASTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Astrotech Corporation (NASDAQ: ASTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $4.71 (-2.69% 1D, market cap $10.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ASTC ranks #872 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ASTC compare to BNGO and EYPT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), ASTC carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 47.5%, and ROIC of -35.0%. By comparison, BNGO (Bionano Genomics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M) and EYPT (EyePoint Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M). Among the 5-stock peer group, ASTC leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ASTC?
▼

Per ASTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001001907), Astrotech Corporation generated $1.0M in revenue (-41.2% YoY), -$13.8M in net income, and -$13.8M in free cash flow against $19.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.68 (-0.67%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510028
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (6)Whales (3)SEC (8)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.6% Base Target
$72 Bull$4 Base$3 Bear
📬 FREE ASTC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ASTC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
🔍 WHY ASTC SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (29% of score)

FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 35 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$6.06-19.6% Next Q
Q2 (-2Q)
33
Grade E$4.87+7.4% Next Q
Q3 (-1Q)
31
Grade E$5.23-9.9% Next Q
Current
28
Grade E$4.71-10% Hist 90D α
Trajectory: E (36) → E (28)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ASTC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ASTC currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.40) and Max Pain ($4.95) forces dealer call-delta covering toward $72.29.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ASTC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ASTC Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 28%NO 72%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 28, 2026 (~54 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.59 Expected Swing
$4.12 (-12.5%)Spot $4.71$5.30 (+12.5%)
MODEL EARNINGS SETUP GAUGE

ASTC Quantitative Pre-Earnings Setup: 28/100

Trailing EPS: $4.25 • YoY Revenue Growth: -41.2%

Model Bullish Setup (28/100)Model Risk Weight (72/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-06-30$1.0M-$13.8M-$13.8M47.5%
FY 20242024-06-30$1.7M-$11.7M-$10.3M44.2%
FY 20232023-06-30$750.0K-$9.6M-$7.6M47.5%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ASTC)

  • ✓Walkthrough of ASTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ASTC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +62.98%⚡ TESTING RESISTANCE
2026-11-03O $5.25H $5.25L $4.71C $4.71VOL 17.9K
RES: $4.93SUP: $4.04SMA50: $6.40SMA200: $7.22
$73.51$54.20$34.88$15.56$-3.75RES $4.93SUP $4.04$4.712026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ASTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ASTC Butterfly Map → + Track ASTC →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -41.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ASTC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ASTC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ASTC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ASTC)

Health Care Rank #872 of 1015 ⚔️ BNGO vs ASTC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ASTC vs. BNGO, EYPT, PRPO, RPID)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Astrotech Corporation (ASTC) ranks #872 by composite RQD confidence (28/100, grade E) and #889 by equity capitalization ($10.2M). Within this direct 5-issuer industry benchmark cohort, ASTC leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. RPID currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with ASTC at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ASTC ACTIVE
Astrotech Corporation
E 28/100 — 47.5% -35.0% -2.69% $10.2M Benchmark Subject
BNGO
Bionano Genomics Inc.
E 29/100 — 46.3% -35.0% +0.87% $16.1M /bngo-vs-astc →
EYPT
EyePoint Inc.
E 26/100 — — -35.0% +7.58% $30.0M /eypt-vs-astc →
PRPO
Precipio Inc.
E 30/100 — 44.2% -7.9% -1.71% $32.4M /prpo-vs-astc →
RPID
Rapid Micro Biosystems Inc. (Class A)
E 34/100 — — -35.0% -4.50% $36.9M /rpid-vs-astc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001001907 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Astrotech Corporation (ASTC) reported GAAP revenue of $1.0M (-41.2% vs. FY2024 revenue of $1.7M , and +33.3% cumulative change since FY2023) , GAAP net income of -$13.8M, operating cash flow of -$13.0M, and free cash flow of -$13.8M (-33.8% YoY). On the balance sheet, ASTC closed FY2025 with $19.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $1.0M -$13.8M -$13.0M -$13.8M $19.7M —
FY2024 (FY) 2024-06-30 $1.7M -$11.7M -$9.7M -$10.3M $31.0M —
FY2023 (FY) 2023-06-30 $750.0K -$9.6M -$7.6M -$7.6M — —

3. ASTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ASTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Astrotech Corporation (NASDAQ: ASTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $4.71 (-2.69% 1D, market cap $10.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ASTC ranks #872 in composite RQD confidence.

How does ASTC compare to BNGO and EYPT in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), ASTC carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 47.5%, and ROIC of -35.0%. By comparison, BNGO (Bionano Genomics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M) and EYPT (EyePoint Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M). Among the 5-stock peer group, ASTC leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ASTC?

Per ASTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001001907), Astrotech Corporation generated $1.0M in revenue (-41.2% YoY), -$13.8M in net income, and -$13.8M in free cash flow against $19.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ASTC trading relative to its 50-day, 200-day, and 52-week technical levels?

ASTC last traded at $4.71 (-2.69% on volume of 31,223 shares), positioning the stock -26.41% below its 50-day simple moving average ($6.40) and -34.76% below its 200-day simple moving average ($7.22). Across its 52-week range of $1.92 to $68.85, ASTC sits at the 4.2% percentile with a 14-day RSI of 35.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.12 to $5.30).

Direct Sub-Reports: ASTC RQD Cockpit ASTC 12M Forecast ASTC Earnings & Move ASTC Dividends & DRIP ASTC Insiders & 13F ASTC Whale Options ASTC Profit Sankey ASTC News & Why
ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ SEC XBRL & RQD VERIFIED

ASTC — Astrotech Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Astrotech Corporation (ASTC) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.71 (-2.69% 1D, market capitalization $10.2M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 47.5%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Astrotech Corporation (ASTC) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry. Gross margin is reported at 47.5%, while operating and net margins are both reported at -60%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Astrotech Corporation (ASTC) reported $1.0M in annual revenue (up from $1.7M in FY2024, -41.2% YoY) and -$13.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($750.0K revenue, -$9.6M net income) through FY2025, ASTC scaled operating cash flow to -$13.0M and free cash flow to -$13.8M, backed by $19.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.92 – $68.85 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector-level context provided is the Health Care sector and Biotechnology: Laboratory Analytical Instruments industry classification. A prospective investor should watch whether the NASA-related lunar infrastructure proposal translates into revenue, since the source does not establish any link between that activity and the reported health-care industry classification.

  • Key Question #1: Can ASTC sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.0M and free cash flow of -$13.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ASTC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ASTC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Astrotech Corporation (ASTC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ASTC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ASTC Bull vs. Bear Conversation Board — What's Your Call at $4.71?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ASTC 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ASTC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $5.57 (+15.1%)
📌 Pinned Debate

Recent news flow includes a NASA NextSTEP-3 lunar power infrastructure proposal, a potential new revenue avenue not reflected in the re

Recent news flow includes a NASA NextSTEP-3 lunar power infrastructure proposal, a potential new revenue avenue not reflected in the reported financials.. When you look under the hood at ASTC, Fundamental Cash Engine is 6/20 with 47.5% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $68.85. My 12M target is $5.57.

SectorRotator 🐂 BULL

@SiliconVal_Bull Agree on the RQD 28/100 quality, though with 1.0 beta I'm scaling in with half-size at $4.84 and keeping dry powder in case we test $4.50.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $3.82 (-21.1%)
Spot @ $4.84

Operating losses widened every year from -$11.1M to -$14.7M while revenue fell to $1.0M, and the RQD cash-engine pillar scored 6/20.

Fading this rally in ASTC at $4.84. Operating losses widened every year from -$11.1M to -$14.7M while revenue fell to $1.0M, and the RQD cash-engine pillar scored 6/20.. With a beta of 1.0 and the stock sitting at $4.84 (52-wk range $1.92–$68.85), the easy multiple expansion is already priced in.

LIVE TAPE